<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="1da8e5bc-aeb7-4168-a8c3-e1d9a9d167ea"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use LEVOTHYROXINE SODIUM FOR INJECTION safely and effectively. See full prescribing information for LEVOTHYROXINE SODIUM FOR INJECTION.  <br/>
      <br/>
      <br/>
      <br/> LEVOTHYROXINE SODIUM for injection, for intravenous use  <br/>
      <br/> Initial U.S. Approval: 1969 </title>
   <effectiveTime value="20250417"/>
   <setId root="ce990712-49c1-4f66-9ee4-c770e8ec394c"/>
   <versionNumber value="7"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="608775388" root="1.3.6.1.4.1.519.1"/>
            <name>Fresenius Kabi USA, LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="023648251" root="1.3.6.1.4.1.519.1"/>
                        <name>Fresenius Kabi USA, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-647" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-648" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-649" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-647" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-648" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-649" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="4feccaca-270a-480f-8b05-38c17c7ce3da"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250417"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="63323-647" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Levothyroxine Sodium</name>
                        <formCode code="C42957" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>LEVOTHYROXINE SODIUM ANHYDROUS</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="ug" value="200"/>
                              <denominator unit="mL" value="5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="054I36CPMN" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LEVOTHYROXINE SODIUM ANHYDROUS</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Q51BO43MG4" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LEVOTHYROXINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="63323-647-10" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20110624"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA202231" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20110624"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="63323-648" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Levothyroxine Sodium</name>
                        <formCode code="C42957" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>LEVOTHYROXINE SODIUM ANHYDROUS</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="ug" value="500"/>
                              <denominator unit="mL" value="5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="054I36CPMN" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LEVOTHYROXINE SODIUM ANHYDROUS</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Q51BO43MG4" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LEVOTHYROXINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="63323-648-10" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20110624"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA202231" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20110624"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="63323-649" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Levothyroxine Sodium</name>
                        <formCode code="C42957" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>LEVOTHYROXINE SODIUM ANHYDROUS</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="ug" value="100"/>
                              <denominator unit="mL" value="5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="054I36CPMN" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LEVOTHYROXINE SODIUM ANHYDROUS</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Q51BO43MG4" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LEVOTHYROXINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="63323-649-07" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20110624"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA202231" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20110624"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="bf485c24-2496-4d04-a775-bc040b424a4f">
               <id root="def333a6-094e-4184-adab-c3ec4e6141e9"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="Boxed Warning section"/>
               <title>WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Thyroid hormones, including Levothyroxine Sodium for Injection, should not be used for the treatment of obesity or for weight loss. (<linkHtml href="#c28f026a-36b1-4a38-8eb2-b798394fee69">5.3</linkHtml>)                  </content>
                     <br/>
                     <content styleCode="bold">Larger doses may produce serious or even life threatening manifestations of toxicity. (<linkHtml href="#eb69a74f-31dc-466d-975d-e520deb810a6">6</linkHtml>)</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250417"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics"/>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Thyroid hormones, including Levothyroxine Sodium for Injection, should not be used</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">for the treatment of obesity or for weight loss. (<linkHtml href="#c28f026a-36b1-4a38-8eb2-b798394fee69">5.3</linkHtml>)</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Larger doses may produce serious or even life threatening manifestations of toxicity. (<linkHtml href="#eb69a74f-31dc-466d-975d-e520deb810a6">6</linkHtml>)</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="c6b93fea-ffef-43df-9c35-d339338ec3b9">
               <id root="9b0ae17f-e37f-4303-bd55-60fdba3260d6"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Levothyroxine Sodium for Injection is indicated for the treatment of myxedema coma. Important Limitations of Use: The relative bioavailability between Levothyroxine Sodium for Injection and oral levothyroxine products has not been established. Caution should be used when switching patients from oral levothyroxine products to Levothyroxine Sodium for Injection as accurate dosing conversion has not been studied.</paragraph>
               </text>
               <effectiveTime value="20250417"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Levothyroxine Sodium is an L-thyroxine product. Levothyroxine (T<sub>4</sub>) Sodium for Injection is indicated for the treatment of myxedema coma. (<linkHtml href="#c6b93fea-ffef-43df-9c35-d339338ec3b9">1</linkHtml>)              </paragraph>
                        <paragraph>
                           <content styleCode="bold">Important Limitations of Use:</content>
                        </paragraph>
                        <paragraph>The relative bioavailability of this drug has not been established. Use caution when converting patients from oral to intravenous levothyroxine. (<linkHtml href="#c6b93fea-ffef-43df-9c35-d339338ec3b9">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="dfcfc32b-c13f-4147-a147-73c239c45cec">
               <id root="9e88e9e3-47da-4b75-a79b-cb714ce5b8b2"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250417"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>An initial intravenous loading dose of Levothyroxine Sodium for Injection between 300 to 500 mcg followed by once daily intravenous maintenance doses between 50 and 100 mcg should be administered, as clinically indicated, until the patient can tolerate oral therapy. (<linkHtml href="#b704b0d7-70cf-4762-8bb9-8a4f7da7dca3">2.1</linkHtml>)                 </item>
                           <item>
                              <caption>•</caption>Reconstitute the lyophilized Levothyroxine Sodium for Injection by aseptically adding 5 mL of 0.9% Sodium Chloride Injection, USP. Shake vial to ensure complete mixing. Reconstituted drug product is preservative free. Use immediately after reconstitution. Discard any unused portion. (<linkHtml href="#c30c456e-aba1-45ef-b3a2-1661208a39f3">2.3</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Do not add to other IV fluids. (<linkHtml href="#c30c456e-aba1-45ef-b3a2-1661208a39f3">2.3</linkHtml>)                 </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="b704b0d7-70cf-4762-8bb9-8a4f7da7dca3">
                     <id root="efa0053a-7e4a-48f1-9830-a445b599455e"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>2.1 Dosage</title>
                     <text>
                        <paragraph>An initial intravenous loading dose of Levothyroxine Sodium for Injection between 300 to 500 mcg, followed by once daily intravenous maintenance doses between 50 and 100 mcg, should be administered, as clinically indicated, until the patient can tolerate oral therapy. The age, general physical condition, cardiac risk factors, and clinical severity of myxedema and duration of myxedema symptoms should be considered when determining the starting and maintenance dosages of Levothyroxine Sodium for Injection.</paragraph>
                        <paragraph>Levothyroxine Sodium for Injection produces a gradual increase in the circulating concentrations of the hormone with an approximate half-life of 9 to 10 days in hypothyroid patients. Daily administration of Levothyroxine Sodium for Injection should be maintained until the patient is capable of tolerating an oral dose and is clinically stable. For chronic treatment of hypothyroidism, an oral dosage form of levothyroxine should be used to maintain a euthyroid state. Relative bioavailability between Levothyroxine Sodium for Injection and oral levothyroxine products has not been established. Based on medical practice, the relative bioavailability between oral and intravenous administration of Levothyroxine Sodium for Injection is estimated to be from 48 to 74%. Due to differences in absorption characteristics of patients and the oral levothyroxine product formulations, TSH and thyroid hormone levels should be measured a few weeks after initiating oral levothyroxine and dose adjusted accordingly.</paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
               <component>
                  <section ID="b4cb3007-03d5-4008-8670-b1cf9088c37c">
                     <id root="bcf1c47f-ab5b-44a6-838e-fd47c0b3542b"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>2.2 Dosing in the Elderly and in Patients with Cardiovascular Disease</title>
                     <text>
                        <paragraph>Intravenous levothyroxine may be associated with cardiac toxicity-including arrhythmias, tachycardia, myocardial ischemia and infarction, or worsening of congestive heart failure and death-in the elderly and in those with underlying cardiovascular disease. Therefore, cautious use, including doses in the lower end of the recommended range, may be warranted in these populations.</paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
               <component>
                  <section ID="c30c456e-aba1-45ef-b3a2-1661208a39f3">
                     <id root="f0437cd8-8da2-4cb3-abcb-1df1c016ff44"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>2.3 Reconstitution Directions</title>
                     <text>
                        <paragraph>Reconstitute the lyophilized Levothyroxine Sodium for Injection by aseptically adding 5 mL of 0.9% Sodium Chloride Injection, USP only. Shake vial to ensure complete mixing. The resultant solution will have a final concentration of approximately 20 mcg per mL, 40 mcg per mL and 100 mcg per mL for the 100 mcg, 200 mcg and 500 mcg vials, respectively. Reconstituted drug product is preservative free and is stable for 4 hours. Discard any unused portion. DO NOT ADD LEVOTHYROXINE SODIUM FOR INJECTION TO OTHER IV FLUIDS. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="c98f7851-bf09-483d-b9b4-529fd6fe747a">
               <id root="bffd78d9-b40b-4fb9-b128-2f09060f4449"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Levothyroxine Sodium for Injection is supplied as a lyophilized powder at three strengths in single dose amber-colored vials: 100 mcg, 200 mcg and 500 mcg. </paragraph>
               </text>
               <effectiveTime value="20250417"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Lyophilized powder for injection in single dose vials: 100 mcg, 200 mcg and 500 mcg. (<linkHtml href="#c98f7851-bf09-483d-b9b4-529fd6fe747a">3</linkHtml>)       </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="b94deae2-f43d-459d-9da7-a25f41e19a39">
               <id root="d7c77075-b506-42f8-aade-426619226ac3"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20250417"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None. (<linkHtml href="#b94deae2-f43d-459d-9da7-a25f41e19a39">4</linkHtml>)       </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="e3fb0346-5aeb-44ff-8e2d-408c68ee5a7b">
               <id root="0eb6ac52-c2db-4ed4-ba1e-598d69c97682"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250417"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Excessive bolus doses of Levothyroxine Sodium for Injection (&gt; 500 mcg) are associated with cardiac complications, particularly in the elderly and in patients with an underlying cardiac condition. Initiate therapy with doses at the lower end of the recommended range. (<linkHtml href="#d696a2c7-626a-4eca-aad9-d29049610b13">5.1</linkHtml>)         </item>
                           <item>
                              <caption>•</caption>Close observation of the patient following the administration of Levothyroxine Sodium for Injection is advised. (<linkHtml href="#d696a2c7-626a-4eca-aad9-d29049610b13">5.1</linkHtml>)         </item>
                           <item>
                              <caption>•</caption>Levothyroxine Sodium for Injection therapy for patients with previously undiagnosed endocrine disorders, including adrenal insufficiency, hypopituitarism, and diabetes insipidus, may worsen symptoms of these endocrinopathies. (<linkHtml href="#b782dff6-8328-417d-9a87-c17c5ae3815f">5.2</linkHtml>)         </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="d696a2c7-626a-4eca-aad9-d29049610b13">
                     <id root="22e103ba-6e35-4a8d-92d8-e026dda396f1"/>
                     <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
                     <title>5.1 Risk of Cardiac Complications in Elderly and in Patients with Cardiovascular Disease</title>
                     <text>
                        <paragraph>Excessive bolus dosing of Levothyroxine Sodium for Injection (greater than 500 mcg) are associated with cardiac complications, particularly in the elderly and in patients with an underlying cardiac condition. Adverse events that can potentially be related to the administration of large doses of Levothyroxine Sodium for Injection include arrhythmias, tachycardia, myocardial ischemia and infarction, or worsening of congestive heart failure and death. Cautious use, including doses in the lower end of the recommended range, may be warranted in these populations. Close observation of the patient following the administration of Levothyroxine Sodium for Injection is advised. </paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
               <component>
                  <section ID="b782dff6-8328-417d-9a87-c17c5ae3815f">
                     <id root="f40c2341-dbca-4058-a5f6-fe463ccbbed5"/>
                     <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
                     <title>5.2 Need for Concomitant Glucocorticoids and Monitoring for Other Diseases in Patients with Endocrine Disorders</title>
                     <text>
                        <paragraph>Occasionally, chronic autoimmune thyroiditis, which can lead to myxedema coma, may occur in association with other autoimmune disorders such as adrenal insufficiency, pernicious anemia, and insulin‑dependent diabetes mellitus. Patients should be treated with replacement glucocorticoids prior to initiation of treatment with Levothyroxine Sodium for Injection, until adrenal function has been adequately assessed. Failure to do so may precipitate an acute adrenal crisis when thyroid hormone therapy is initiated, due to increased metabolic clearance of glucocorticoids by thyroid hormone. With initiation of Levothyroxine Sodium for Injection, patients with myxedema coma should also be monitored for previously undiagnosed diabetes insipidus. </paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
               <component>
                  <section ID="c28f026a-36b1-4a38-8eb2-b798394fee69">
                     <id root="630cc7a2-87e7-4b3f-9fe7-b51dcfd47e39"/>
                     <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
                     <title>5.3 Not Indicated for Treatment of Obesity</title>
                     <text>
                        <paragraph>Thyroid hormones, including Levothyroxine Sodium for Injection, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#eb69a74f-31dc-466d-975d-e520deb810a6">6</linkHtml>) and Overdosage (<linkHtml href="#bcda84b4-e1af-47c4-8a17-9fc44a27969c">10</linkHtml>)]. </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="eb69a74f-31dc-466d-975d-e520deb810a6">
               <id root="1c6c4cee-9c2a-4a89-b6e1-f8267dc9faaa"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Excessive doses of levothyroxine can predispose to signs and symptoms compatible with hyperthyroidism. The signs and symptoms of thyrotoxicosis include, but are not limited to: exophthalmic goiter, weight loss, increased appetite, palpitations, nervousness, diarrhea, abdominal cramps, sweating, tachycardia, increased pulse and blood pressure, cardiac arrhythmias, angina pectoris, tremors, insomnia, heat intolerance, fever, and menstrual irregularities. </paragraph>
               </text>
               <effectiveTime value="20250417"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Excessive doses of L-thyroxine can predispose to signs and symptoms compatible with hyperthyroidism</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="c1d9df17-7bb7-4c7c-a9d7-9e6239cd3f6d">
               <id root="2eea20f4-5d9f-41b0-badd-47f6b1bc0a78"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>Many drugs affect thyroid hormone pharmacokinetics and metabolism (e.g., synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to Levothyroxine Sodium for Injection. In addition, thyroid hormones and thyroid status have varied effects on the pharmacokinetics and actions of other drugs (see Section <linkHtml href="#e3bfe820-fed8-4540-b4a3-9b31a8214ea3">12.3</linkHtml>).   </paragraph>
               </text>
               <effectiveTime value="20250417"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Many drugs affect thyroid hormone pharmacokinetics and metabolism (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to Levothyroxine Sodium for Injection. (<linkHtml href="#c1d9df17-7bb7-4c7c-a9d7-9e6239cd3f6d">7</linkHtml>, <linkHtml href="#e3bfe820-fed8-4540-b4a3-9b31a8214ea3">12.3</linkHtml>)    </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="cf43332a-ab08-493b-a484-c72977aa141e">
                     <id root="c036329d-7376-4bf7-ace9-2b18f82a1ebf"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>7.1 Antidiabetic Therapy</title>
                     <text>
                        <paragraph>Addition of levothyroxine to antidiabetic or insulin therapy may result in increased antidiabetic agent or insulin requirements. Careful monitoring of diabetic control is recommended, especially when thyroid therapy is started, changed, or discontinued.</paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
               <component>
                  <section ID="cfb5bdec-7316-4688-9a4b-4b091915e7fc">
                     <id root="ea4705e7-72da-4a10-9ac4-696ff11084ed"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>7.2 Oral Anticoagulants</title>
                     <text>
                        <paragraph>Levothyroxine increases the response to oral anticoagulant therapy. Therefore, a decrease in the dose of anticoagulant may be warranted with correction of the hypothyroid state or when the Levothyroxine Sodium for Injection dose is increased. Prothrombin time should be closely monitored to permit appropriate and timely dosage adjustments.</paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
               <component>
                  <section ID="d54f7f54-98f5-497d-9a13-e4f18495e3f4">
                     <id root="d2038905-0031-4d37-b8ce-3630df109ad1"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>7.3 Digitalis Glycosides</title>
                     <text>
                        <paragraph>The therapeutic effects of digitalis glycosides may be reduced by levothyroxine. Serum digitalis glycoside levels may be decreased when a hypothyroid patient becomes euthyroid, necessitating an increase in the dose of digitalis glycosides.</paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
               <component>
                  <section ID="ea77e25b-e6c3-405d-822b-3af0d89f4dc7">
                     <id root="37f12631-ef42-4c0a-9605-8ab68fbae3c2"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>7.4 Antidepressant Therapy</title>
                     <text>
                        <paragraph>Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and levothyroxine may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. Toxic effects may include increased risk of cardiac arrhythmias and CNS stimulation; onset of action of tricyclics may be accelerated. Administration of sertraline in patients stabilized on levothyroxine may result in increased levothyroxine requirements.</paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
               <component>
                  <section ID="a0150bad-423d-471b-bde2-8071d8c793a8">
                     <id root="290b9b2d-90dc-4b23-b8f1-1b456db04851"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>7.5 Ketamine</title>
                     <text>
                        <paragraph>Concurrent use may produce marked hypertension and tachycardia; cautious administration to patients receiving thyroid hormone therapy is recommended.</paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
               <component>
                  <section ID="ab2aca05-49ef-4624-97b0-13cbbe1f3e65">
                     <id root="ca0693cd-c47d-43ed-a406-fb170794a50f"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>7.6 Sympathomimetics</title>
                     <text>
                        <paragraph>Concurrent use may increase the effects of sympathomimetics or thyroid hormone. Thyroid hormones may increase the risk of coronary insufficiency when sympathomimetic agents are administered to patients with coronary artery disease.</paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
               <component>
                  <section ID="e2753e7d-f1bc-4c05-81a1-f3c20d57d702">
                     <id root="1a49b2c3-dcfe-48d4-b833-db5106ea6bba"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>7.7 Drug-Laboratory Test Interactions</title>
                     <text>
                        <paragraph>Changes in thyroxine binding globulin (TBG) concentration must be considered when interpreting levothyroxine and triiodothyronine values, which necessitates measurement and evaluation of unbound (free) hormone and/or determination of the free levothyroxine index. Pregnancy, infectious hepatitis, estrogens, estrogen containing oral contraceptives, and acute intermittent porphyria increase TBG concentrations. Decreases in TBG concentrations are observed in nephrosis, severe hypoproteinemia, severe liver disease, acromegaly, and after androgen or corticosteroid therapy. Familial hyper or hypo thyroxine binding globulinemias have been described, with the incidence of TBG deficiency approximating 1 in 9,000.</paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="a2371cc3-d59e-4d08-8a9d-50d18ceba759">
               <id root="690f6548-660d-482d-a4d4-4d6e79a403c5"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250417"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Elderly and those with underlying cardiovascular disease should receive doses at the lower end of the recommended range. (<linkHtml href="#c858e7cd-539b-4da1-bddd-9304fd0c155b">8.5</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="c92214a9-3929-40f9-9131-c5d97b91a7d5">
                     <id root="51f11f31-bd20-4578-afaf-db455fedbf3d"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Pregnancy Category A</content> – There are no reported cases of Levothyroxine Sodium for Injection used to treat myxedema coma in patients who were pregnant or lactating. Studies in pregnant women treated with oral levothyroxine to maintain a euthyroid state have not shown an increased risk of fetal abnormalities. Therefore, pregnant patients who develop myxedema should be treated with Levothyroxine Sodium for Injection as the risk of nontreatment is associated with a high probability of significant morbidity or mortality to the maternal patient and the fetus.    </paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
               <component>
                  <section ID="ee44e315-3405-45e2-9eab-9df7e7832a97">
                     <id root="b2d99b11-0201-4d7c-85ea-82d63389a0e8"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>8.2 Labor and Delivery</title>
                     <text>
                        <paragraph>Patients in labor who develop myxedema have not been reported in the literature. However, patients should be treated with Levothyroxine Sodium for Injection as the risk of nontreatment is associated with a high probability of significant morbidity or mortality to the maternal patient and the fetus.</paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
               <component>
                  <section ID="bac718b0-0589-43c9-a856-9311c141c469">
                     <id root="e93b467f-58dd-4249-9d84-49e507326e11"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.3 Nursing Mothers</title>
                     <text>
                        <paragraph>Adequate replacement doses of thyroid hormones are required to maintain normal lactation. There are no reported cases of Levothyroxine Sodium for Injection used to treat myxedema coma in patients who are lactating. However, such patients should be treated with Levothyroxine Sodium for Injection as the risk of nontreatment is associated with a high probability of significant morbidity or mortality to the nursing patient.</paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
               <component>
                  <section ID="eecd097b-46a8-4004-aadb-f0e3f5facbe6">
                     <id root="57e8b473-a150-48dc-8b98-db32669c960c"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Myxedema coma is a disease of the elderly. An approved, oral dosage form of levothyroxine should be used in the pediatric patient population for maintaining a euthyroid state in non-complicated hypothyroidism.</paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
               <component>
                  <section ID="c858e7cd-539b-4da1-bddd-9304fd0c155b">
                     <id root="2494e61f-98d6-4783-b445-a5816ca2929b"/>
                     <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
                     <title>8.5 Geriatric Use and Patients with Underlying Cardiovascular Disease</title>
                     <text>
                        <paragraph>See Section 2, <linkHtml href="#dfcfc32b-c13f-4147-a147-73c239c45cec">Dosage and Administration</linkHtml>, for full prescribing information in the geriatric patient population. Because of the increased prevalence of cardiovascular disease in the elderly, cautious use of Levothyroxine Sodium for Injection in the elderly and in patients with known cardiac risk factors is advised. Atrial fibrillation is a common side effect associated with levothyroxine treatment in the elderly <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#dfcfc32b-c13f-4147-a147-73c239c45cec">2</linkHtml>) and Warnings and Precautions (<linkHtml href="#e3fb0346-5aeb-44ff-8e2d-408c68ee5a7b">5</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="bcda84b4-e1af-47c4-8a17-9fc44a27969c">
               <id root="2d3da5b9-023e-410d-8871-c6766a57c6b4"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>In general, the signs and symptoms of overdosage with levothyroxine are those of hyperthyroidism <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#e3fb0346-5aeb-44ff-8e2d-408c68ee5a7b">5</linkHtml>) and Adverse Reactions (<linkHtml href="#eb69a74f-31dc-466d-975d-e520deb810a6">6</linkHtml>)]</content>. In addition, confusion and disorientation may occur. Cerebral embolism, shock, coma, and death have been reported. Excessive doses of Levothyroxine Sodium for Injection (greater than 500 mcg) are associated with cardiac complications in patients with underlying cardiac disease.    <br/>
                     <br/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Treatment of Overdosage</content>
                  </paragraph>
                  <paragraph>Levothyroxine Sodium for Injection should be reduced in dose or temporarily discontinued if signs or symptoms of overdosage occur. To obtain up-to-date information about the treatment of overdose, a good resource is the certified Regional Poison Control Center. In managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in the patient.</paragraph>
                  <paragraph>In the event of an overdose, appropriate supportive treatment should be initiated as dictated by the patient's medical status.</paragraph>
               </text>
               <effectiveTime value="20250417"/>
            </section>
         </component>
         <component>
            <section ID="b36b0064-5e0a-4d69-9af3-6638da326657">
               <id root="6e39e07a-4084-4e44-bb03-33d38d872cd0"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Levothyroxine Sodium for Injection contains synthetic crystalline levothyroxine (L-thyroxine) sodium salt. Levothyroxine sodium has an empirical formula of C<sub>15</sub>H<sub>10</sub>I<sub>4</sub>NNaO<sub>4</sub>, a molecular weight of 798.85 g/mol (anhydrous), and the following structural formula:   </paragraph>
                  <paragraph>
                     <renderMultiMedia ID="id749" referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>Levothyroxine Sodium for Injection is a sterile, preservative-free lyophilized powder consisting of the active ingredient, levothyroxine sodium, and the excipients dibasic sodium phosphate heptahydrate, USP; mannitol, USP; and sodium hydroxide, NF in single dose amber glass vials. Levothyroxine Sodium for Injection is available at three dosage strengths: 100 mcg per vial, 200 mcg per vial and 500 mcg per vial.</paragraph>
               </text>
               <effectiveTime value="20250417"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>levot-struc-01.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="levot-struc-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="e35ed810-4167-4332-a871-22a4cf7396ad">
               <id root="e6963ebc-13af-45c1-8a68-a2eed5bb9969"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250417"/>
               <component>
                  <section ID="c14d8b25-894a-452a-956f-4f64e9143782">
                     <id root="56d69198-7400-4623-8d59-4e3d42fe47d7"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis. Triiodothyronine (T<sub>3</sub>) and levothyroxine (T<sub>4</sub>) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins.     <br/>
                           <br/>
                        </paragraph>
                        <paragraph>The physiological actions of thyroid hormones are produced predominantly by T<sub>3</sub>, the majority of which (approximately 80%) is derived from T<sub>4</sub> by deiodination in peripheral tissues.   </paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
               <component>
                  <section ID="a923d6ae-6a16-48fc-9176-9fb3df9ea3a5">
                     <id root="0d625a99-f5a3-4f0d-8144-7c6ffa5df154"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Thyroid hormone synthesis and secretion is regulated by the hypothalamic pituitary-thyroid axis. Thyrotropin releasing hormone (TRH) released from the hypothalamus stimulates secretion of thyrotropin stimulating hormone (TSH) from the anterior pituitary. TSH, in turn, is the physiologic stimulus for the synthesis and secretion of thyroid hormones, T<sub>4</sub> and T<sub>3</sub>, by the thyroid gland. Circulating serum T<sub>3</sub> and T<sub>4</sub> levels exert a feedback effect on both TRH and TSH secretion. When serum T<sub>3</sub> and T<sub>4</sub> levels increase, TRH and TSH secretion decrease. When thyroid hormone levels decrease, TRH and TSH secretion increases. TSH is used for the diagnosis of hypothyroidism and evaluation of levothyroxine therapy adequacy with other laboratory and clinical data <content styleCode="italics">[see Dosage (<linkHtml href="#b704b0d7-70cf-4762-8bb9-8a4f7da7dca3">2.1</linkHtml>)].</content> There are drugs known to affect thyroid hormones and TSH by various mechanisms and those examples are diazepam, ethioamide, lovastatin, metoclopramide, 6-mercaptopurine, nitroprusside, perphenazine, and thiazide diuretics. Some drugs may cause a transient decrease in TSH secretion without hypothyroidism and those drugs (dose) are dopamine (greater than 1 mcg per kg per min), glucocorticoids (hydrocortisone greater than 100 mg per day or equivalent) and octreotide (greater than 100 mcg per day).    <br/>
                           <br/>
                        </paragraph>
                        <paragraph>Thyroid hormones regulate multiple metabolic processes and play an essential role in normal growth and development, and normal maturation of the central nervous system and bone. The metabolic actions of thyroid hormones include augmentation of cellular respiration and thermogenesis, as well as metabolism of proteins, carbohydrates and lipids. The protein anabolic effects of thyroid hormones are essential to normal growth and development.</paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
               <component>
                  <section ID="e3bfe820-fed8-4540-b4a3-9b31a8214ea3">
                     <id root="6acdaf86-919d-4808-ab4f-6c861419ae0c"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Absorption </content>– Levothyroxine Sodium for Injection is administered via the intravenous route. Following administration, the synthetic levothyroxine cannot be distinguished from the natural hormone that is secreted endogenously.       </paragraph>
                        <paragraph>
                           <content styleCode="bold">Distribution </content>– Circulating thyroid hormones are greater than 99% bound to plasma proteins, including thyroxine binding globulin (TBG), thyroxine binding prealbumin (TBPA), and albumin (TBA), whose capacities and affinities vary for each hormone. The higher affinity of both TBG and TBPA for T<sub>4</sub> partially explains the higher serum levels, slower metabolic clearance, and longer half life of T<sub>4</sub> compared to T<sub>3</sub>. Protein bound thyroid hormones exist in reverse equilibrium with small amounts of free hormone. Only unbound hormone is metabolically active. Many drugs and physiologic conditions affect the binding of thyroid hormones to serum proteins <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#e3fb0346-5aeb-44ff-8e2d-408c68ee5a7b">5</linkHtml>) and Drug Interactions (<linkHtml href="#c1d9df17-7bb7-4c7c-a9d7-9e6239cd3f6d">7</linkHtml>)]</content>. Thyroid hormones do not readily cross the placental barrier <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#e3fb0346-5aeb-44ff-8e2d-408c68ee5a7b">5</linkHtml>) and Use in Specific Populations (<linkHtml href="#a2371cc3-d59e-4d08-8a9d-50d18ceba759">8</linkHtml>)]</content>.   </paragraph>
                        <paragraph>
                           <content styleCode="bold">Metabolism </content>– T<sub>4</sub> is slowly eliminated. The major pathway of thyroid hormone metabolism is through sequential deiodination. Approximately eighty percent of circulating T<sub>3</sub> is derived from peripheral T<sub>4</sub> by monodeiodination. The liver is the major site of degradation for both T<sub>4</sub> and T<sub>3</sub>, with T<sub>4</sub> deiodination also occurring at a number of additional sites, including the kidney and other tissues. Approximately 80% of the daily dose of T<sub>4</sub> is deiodinated to yield equal amounts of T<sub>3</sub> and reverse T<sub>3</sub> (r T<sub>3</sub>). T<sub>3</sub> and r T<sub>3</sub> are further deiodinated to diiodothyronine. Thyroid hormones are also metabolized via conjugation with glucuronides and sulfates and excreted directly into the bile and gut where they undergo enterohepatic recirculation.      </paragraph>
                        <paragraph>
                           <content styleCode="bold">Elimination</content>– Thyroid hormones are primarily eliminated by the kidneys. A portion of the conjugated hormone reaches the colon unchanged, where it is hydrolyzed and eliminated in feces as the free hormones. Urinary excretion of T<sub>4</sub> decreases with age.            </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 1:</content> Pharmacokinetic Parameters of Thyroid Hormones in Euthyroid Patients            </paragraph>
                        <table cellpadding="0pt" cellspacing="0pt" width="100%">
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Hormone</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Ratio in Thyroglobulin </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Biologic Potency</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Half-Life </content>
                                       <br/>
                                       <content styleCode="bold">(Days)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Protein Binding </content>
                                       <br/>
                                       <content styleCode="bold">(%)<sup>2</sup>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>  T<sub>4</sub>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>10 to 20                        </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>6 to 8<sup>1</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>99.96                        </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>  T<sub>3</sub>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>1                        </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>4                        </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>≤ 2                        </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>99.5                        </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>T<sub>4</sub>: Levothyroxine            <br/>T<sub>3</sub>: Liothyronine               <br/>
                           <sup>1</sup> 3 to 4 days in hyperthyroidism, 9 to 10 days in hypothyroidism.               <br/>
                           <sup>2</sup> Includes TBG, TBPA, and TBA.            </paragraph>
                        <paragraph>
                           <content styleCode="bold">Drug Interactions</content>
                        </paragraph>
                        <paragraph>A listing of drug interaction with T<sub>4</sub> is provided in the following tables, although it may not be comprehensive due to the introduction of new drugs that interact with the thyroidal axis or the discovery of previously unknown interactions. The prescriber should be aware of this fact and should consult appropriate reference sources (e.g., package inserts of newly approved drugs, medical literature) for additional information if a drug-drug interaction with levothyroxine is suspected.   </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 2:</content> Drugs That May Alter T<sub>4</sub> and T<sub>3</sub> Serum Transport Without Affecting free T<sub>4</sub> Concentration (Euthyroidism)      </paragraph>
                        <table cellpadding="0pt" cellspacing="0pt" width="100%">
                           <col width="35%"/>
                           <col width="65%"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Drugs That May Increase Serum TBG Concentration</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Drugs That May Decrease Serum TBG Concentration                         </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Clofibrate                        <br/>Estrogen-containing oral contraceptives                        <br/>
                                       <br/>Estrogens (oral)                        <br/>Heroin/Methadone                        <br/>5-Fluorouracil                        <br/>Mitotane                        <br/>Tamoxifen                        </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Androgens/Anabolic Steroids                        <br/>Asparaginase                        <br/>
                                       <br/>Glucocorticoids                        <br/>Slow-Release Nicotinic Acid                        <br/>
                                       <br/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <br/>
                                       <content styleCode="bold">Drugs That May Cause Protein-Binding Site Displacement</content>
                                    </paragraph>
                                    <paragraph>Potential impact<content styleCode="bold">:</content> Administration of these agents with levothyroxine results in an initial transient increase in FT<sub>4</sub>. Continued administration results in a decrease in serum T<sub>4</sub> and normal FT<sub>4</sub> and TSH concentrations and, therefore, patients are clinically euthyroid.                        <br/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Salicylates (&gt; 2 g/day)                        <br/>                         </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Salicylates inhibit binding of T<sub>4</sub> and T<sub>3</sub> to TBG and transthyretin. An initial increase in serum FT<sub>4</sub> is followed by return of FT<sub>4</sub> to normal levels with sustained therapeutic serum salicylate concentrations, although total-T<sub>4</sub> levels may decrease by as much as 30%.                        </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>Other drugs:                        <br/>Furosemide (&gt; 80 mg IV)                        <br/>
                                       <br/>Heparin                         <br/>Hydantoins                         <br/>Non-Steroidal Anti-inflammatory Drugs                        <br/>- Fenamates                        <br/>- Phenylbutazone                        </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>                         <br/>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">Table 3:</content> Drugs That May Alter Hepatic Metabolism of T<sub>4</sub> (Hypothyroidism)      </paragraph>
                        <paragraph>Potential impact: Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased levothyroxine requirements.<br/>
                        </paragraph>
                        <table cellpadding="0pt" cellspacing="0pt" width="100%">
                           <col width="35%"/>
                           <col width="65%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Drug or Drug Class</content>
                                       <br/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Toprule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Carbamazepine                        <br/>Hydantoins                        <br/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Phenytoin and carbamazepine reduce serum protein binding of levothyroxine, and total- and free- T<sub>4</sub> may be reduced by 20% to 40%, but most patients have normal serum TSH levels and are clinically euthyroid.                        </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>Other drugs:                        <br/>Phenobarbital                        <br/>Rifampin                        </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>                         <br/>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">Table 4:</content> Drugs That May Decrease Conversion of T<sub>4</sub> to T<sub>3</sub>
                        </paragraph>
                        <paragraph>Potential impact: Administration of these enzyme inhibitors decreases the peripheral conversion of T<sub>4</sub> to T<sub>3</sub>, leading to decreased T<sub>3</sub> levels. However, serum T<sub>4</sub> levels are usually normal but may occasionally be slightly increased.            <br/>
                        </paragraph>
                        <table cellpadding="0pt" cellspacing="0pt" width="100%">
                           <col width="35%"/>
                           <col width="65%"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="italics"> </content>
                                       <br/>
                                       <content styleCode="bold">Drug or Drug Class</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="italics"> </content>
                                       <br/>
                                       <content styleCode="bold">Effect</content>
                                       <br/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Beta-adrenergic antagonists                         <br/>(e.g., Propranolol &gt;  160 mg/day)                        <br/>
                                       <br/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>In patients treated with large doses of propranolol (&gt;160 mg/day), T<sub>3</sub> and T<sub>4</sub> levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. It should be noted that actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state.                         </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Glucocorticoids                         <br/>(e.g., Dexamethasone  ≥ 4 mg/day)                        <br/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Short-term administration of large doses of glucocorticoids may decrease serum T<sub>3</sub> concentrations by 30% with minimal change in serum T<sub>4</sub> levels. However, long-term glucocorticoid therapy may result in slightly decreased T<sub>3</sub> and T<sub>4</sub> levels due to decreased TBG production (see above).                        </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>Other drug:                        <br/>Amiodarone                        </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top"/>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="a96dbddc-a2fe-4023-95e1-f194b9fe448c">
               <id root="330d9a83-bfc7-4c78-abad-0e5bf5a2b5ec"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250417"/>
               <component>
                  <section ID="a46bb69f-8ff6-4366-af30-4329c809b4f6">
                     <id root="5a5baea0-de68-4498-9ed5-e9ae705efce0"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Animal studies have not been performed to evaluate the carcinogenic potential, mutagenic potential or effects on fertility of Levothyroxine Sodium for Injection. </paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
               <component>
                  <section ID="be463866-7ff9-4d3f-82ac-3c6ee8099d45">
                     <id root="a5594870-6afa-4a2f-ab11-2439d6db8978"/>
                     <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology and Pharmacology</title>
                     <text>
                        <paragraph>No animal toxicology studies have been conducted with Levothyroxine Sodium for Injection.</paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="bed8e86a-30f9-468d-a537-f3890bd964fe">
               <id root="11ee6a87-78c8-4d41-9051-ae33289a50f1"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>No clinical studies have been conducted with Levothyroxine Sodium for Injection in patients with myxedema coma. However, data from published literature support the intravenous use of levothyroxine sodium for the treatment of myxedema coma.</paragraph>
               </text>
               <effectiveTime value="20250417"/>
            </section>
         </component>
         <component>
            <section ID="c4ae6065-ecc7-44e5-adaa-87f56ec9ab6e">
               <id root="c512fa1e-8cf0-4190-97dc-711aba4d8c8e"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20250417"/>
               <component>
                  <section ID="c8ac7907-5a25-4c2b-bdc2-cf5e94de4a58">
                     <id root="cf2d798c-ab06-4c31-8d94-9f5915f50d5b"/>
                     <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
                     <title>16.1 How Supplied</title>
                     <text>
                        <paragraph>Levothyroxine Sodium for Injection is available in three dosage strengths.</paragraph>
                        <table width="100%">
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Product Code</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Unit of Sale</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Strength</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Reconstituted Concentration</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Each</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>506107</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>NDC 63323-649-07</paragraph>
                                    <paragraph>Individually Packaged</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>100 mcg per vial</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>20 mcg per mL</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>NDC 63323-649-07</paragraph>
                                    <paragraph>Vial</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>506247</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>NDC 63323-647-10</paragraph>
                                    <paragraph>Individually Packaged</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>200 mcg per vial</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>40 mcg per mL</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>NDC 63323-647-10</paragraph>
                                    <paragraph>Vial</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>506248</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>NDC 63323-648-10</paragraph>
                                    <paragraph>Individually Packaged</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>500 mcg per vial</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>100 mcg per mL</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>NDC 63323-648-10</paragraph>
                                    <paragraph>Vial</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250417"/>
                  </section>
               </component>
               <component>
                  <section ID="d42b59ad-37fd-4959-803a-105ae1d8766e">
                     <id root="8a8facd3-1588-4867-8529-f21d3797f6da"/>
                     <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
                     <title>16.2 Storage and Handling</title>
                     <text>
                        <paragraph>Protect from light and store dry product at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Reconstituted drug product is preservative free. Discard any unused portion.</paragraph>
                        <paragraph>This container closure is not made with natural rubber latex.</paragraph>
                        <renderMultiMedia ID="id-366684727" referencedObject="F67FC1E4-EA71-4D16-B648-08AC40C18EDA"/>
                        <paragraph>
                           <br/>www.fresenius-kabi.com/us</paragraph>
                        <paragraph>451253E</paragraph>
                     </text>
                     <effectiveTime value="20250417"/>
                     <component>
                        <observationMedia ID="F67FC1E4-EA71-4D16-B648-08AC40C18EDA">
                           <text>levot-img-01.jpg</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="levot-img-01.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_a37af2fd-5f5b-4091-983c-c6bca763eb66">
               <id root="6c2d68d3-7fc1-4146-a07f-db01c8a210f1"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL - PRINCIPAL DISPLAY - Levothyroxine 100 mcg Single Dose Vial Label   </title>
               <text>
                  <paragraph>NDC 63323-649-07      506107             <br/>
                     <content styleCode="bold">Levothyroxine                 </content>
                     <br/>
                     <content styleCode="bold">Sodium                 </content>
                     <br/>for Injection             <br/>
                     <content styleCode="bold">100 mcg per vial</content>
                  </paragraph>
                  <paragraph>For Intravenous Use             <br/>Single Dose Vial          </paragraph>
                  <paragraph>Discard any unused portion.             <br/>Rx only             </paragraph>
                  <renderMultiMedia ID="id749629201" referencedObject="E2285C62-4C4C-41BD-BFBF-872E21540265"/>
                  <br/>
               </text>
               <effectiveTime value="20250417"/>
               <component>
                  <observationMedia ID="E2285C62-4C4C-41BD-BFBF-872E21540265">
                     <text>levot-label-01.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="levot-label-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_357816e2-32ab-40e1-b662-c71e85285b53">
               <id root="f327365f-edc9-476a-80f6-f5f2af4f9d03"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL - PRINCIPAL DISPLAY - Levothyroxine 100 mcg Single Dose Vial Carton Panel  </title>
               <text>
                  <paragraph>NDC 63323-649-07      506107             <br/>
                     <content styleCode="bold">Levothyroxine                 </content>
                     <br/>
                     <content styleCode="bold">Sodium                 </content>
                     <br/>for Injection             <br/>
                     <content styleCode="bold">100 mcg per vial</content>
                  </paragraph>
                  <paragraph>For Intravenous Use</paragraph>
                  <paragraph>Single Dose Vial</paragraph>
                  <paragraph>Discard any unused              <br/>portion.             <br/>Rx only               </paragraph>
                  <renderMultiMedia ID="id1379048473" referencedObject="AF6BEAE9-F95D-404B-A091-5DFA9932217A"/>
               </text>
               <effectiveTime value="20250417"/>
               <component>
                  <observationMedia ID="AF6BEAE9-F95D-404B-A091-5DFA9932217A">
                     <text>levot-label-02.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="levot-label-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_e6c87d15-598a-45d6-9e9a-d62d5a071f7e">
               <id root="1a8ae213-3539-4b78-a1f8-d567b03ea2af"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL - PRINCIPAL DISPLAY - Levothyroxine 500 mcg Single Dose Vial Label  </title>
               <text>
                  <paragraph>NDC 63323-648-10      506248             <br/>
                     <content styleCode="bold">Levothyroxine                 </content>
                     <br/>
                     <content styleCode="bold">Sodium                 </content>
                     <br/>for Injection             <br/>
                     <content styleCode="bold">500 mcg per viaI</content>
                  </paragraph>
                  <paragraph>For Intravenous Use             <br/>Single Dose Vial          </paragraph>
                  <paragraph>Discard any unused portion.             <br/>Rx only             </paragraph>
                  <renderMultiMedia ID="id-1094324195" referencedObject="ID_6e74f0fe-9c71-4987-947b-d82f474cceb9"/>
               </text>
               <effectiveTime value="20250417"/>
               <component>
                  <observationMedia ID="ID_6e74f0fe-9c71-4987-947b-d82f474cceb9">
                     <text>levot-label-03.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="levot-label-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_7f874406-3aa8-43bb-90d2-db7d4a40120f">
               <id root="4c759a1f-57d8-4d3f-bf70-36946d6042a3"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL - PRINCIPAL DISPLAY - Levothyroxine 500 mcg Single Dose Vial Carton Panel </title>
               <text>
                  <paragraph>NDC 63323-648-10      506248             <br/>
                     <content styleCode="bold">Levothyroxine                 </content>
                     <br/>
                     <content styleCode="bold">Sodium                 </content>
                     <br/>for Injection             <br/>
                     <content styleCode="bold">500 mcg per vial</content>
                  </paragraph>
                  <paragraph>For Intravenous Use             <br/>Single Dose Vial          </paragraph>
                  <paragraph>Discard any unused             <br/>portion.             <br/>Rx only             <br/>
                     <br/>
                     <renderMultiMedia ID="id50510598" referencedObject="ID_8a67cfeb-207d-42fd-96b4-5fe0a01087b5"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250417"/>
               <component>
                  <observationMedia ID="ID_8a67cfeb-207d-42fd-96b4-5fe0a01087b5">
                     <text>levot-label-04.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="levot-label-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_80aa8f66-fbf5-4056-88ad-c90f51dc3023">
               <id root="df22ea7c-3877-4603-8e6f-c7478590902e"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL - PRINCIPAL DISPLAY - Levothyroxine 200 mcg Single Dose Vial Label </title>
               <text>
                  <paragraph>NDC 63323-647-10      506247             <br/>
                     <content styleCode="bold">Levothyroxine                 </content>
                     <br/>
                     <content styleCode="bold">Sodium                 </content>
                     <br/>for Injection             <br/>
                     <content styleCode="bold">200 mcg per vial</content>
                  </paragraph>
                  <paragraph>For Intravenous Use</paragraph>
                  <paragraph>Single Dose Vial</paragraph>
                  <paragraph>Discard any unused portion.             <br/>Rx only             <br/>
                     <br/>
                     <renderMultiMedia ID="id22602114" referencedObject="ID_366b3872-d335-47a6-a710-c2be4a1b0609"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250417"/>
               <component>
                  <observationMedia ID="ID_366b3872-d335-47a6-a710-c2be4a1b0609">
                     <text>levot-label-05.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="levot-label-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_b098bcdd-7110-464a-8432-4b307d029bd4">
               <id root="6ad47505-e10a-45e4-bc57-5f271076e598"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL - PRINCIPAL DISPLAY - Levothyroxine 200 mcg Single Dose Vial Carton Panel  </title>
               <text>
                  <paragraph>NDC 63323-647-10      506247             <br/>
                     <content styleCode="bold">Levothyroxine                 </content>
                     <br/>
                     <content styleCode="bold">Sodium                 </content>
                     <br/>for Injection             <br/>
                     <content styleCode="bold">200 mcg per vial</content>
                  </paragraph>
                  <paragraph>For Intravenous Use</paragraph>
                  <paragraph>Single Dose Vial</paragraph>
                  <paragraph>Discard any unused             <br/>portion.             <br/>Rx only             <br/>
                     <br/>
                     <renderMultiMedia ID="id-729769865" referencedObject="E92A953B-A6D5-4286-B249-F781A83F171A"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250417"/>
               <component>
                  <observationMedia ID="E92A953B-A6D5-4286-B249-F781A83F171A">
                     <text>levot-label-06.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="levot-label-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>